Dementia of the Alzheimer Type
The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Dementia of the Alzheimer type is a progressive, fatal neurodegenerative condition characterized by deterioration in cognition and memory, progressive impairment in the ability to carry out activities of daily living, and a number of neuropsychiatric symptoms. This narrative review summarizes the literature regarding descriptive epidemiology, clinical course, and characteristic neuropathological changes of dementia of the Alzheimer type. Although there are no definitive imaging or laboratory tests, except for brain biopsy, for diagnosis, brief screening instruments and neuropsychiatric test batteries used to assess the disease are discussed. Insufficient evidence exists for the use of biomarkers in clinical practice for diagnosis or disease management, but promising discoveries are summarized. Optimal treatment requires both nonpharmacological and pharmacological interventions, yet none have been shown to modify the disease's clinical course. This review describes the current available options and summarizes promising new avenues for treatment. Issues related to the care of persons with dementia of the Alzheimer type, including caregiver burden, long-term care, and the proliferation of dementia special care units, are discussed. Although advances have been made, more research is needed to address the gaps in our understanding of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“Earlier age at onset is observed in a dose-dependent fashion (the average age at onset for persons with genotype e4/e4, only one e4 allele, and no e4 allele is 68 years, 76 years, and 84 years, respectively) (101).”
BackgroundThe Mini‐Mental State Examination: A Comprehensive Review
Tombaugh, T. N., & McIntyre, N. J. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb01992.x · Cited by 5,152 · cited 2×
“MMSE scores are affected by gender, educational attainment, age, and cultural background (143, 147, 148); the sensitivity of the MMSE is poor for patients with mild dementia (2, 149); the instrument is considered too time-consuming to administer in routine clinical practice (150, 151); not all changes in MMSE scores n…”
BackgroundMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Moms, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., Fillenbaum, G., Mellits, E. D., & Clark, C. (1989) · Neurology · doi:10.1212/wnl.39.9.1159 · Cited by 4,130
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 4×
“Modifications, alternatives, and supplements to the MMSE such as the modified version of the MMSE (155); the Montreal Cognitive Assessment (156); the Memory Impairment Screen (157); the Blessed Test of Information, Memory, and Concentration (158) and its abridged version, the Short Blessed Test (159); the OneMinute Ve…”
BackgroundInfluentialCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
Caregiving as a Risk Factor for Mortality: The Caregiver Health Effects Study
Schulz, R., & Beach, S. R. (1999) · JAMA · doi:10.1001/jama.282.23.2215 · Cited by 3,340 · cited 1×
“Informal caregivers report higher levels of depression and anxiety (255– 259), lower overall life satisfaction (257, 260), and engaging in fewer preventive health behaviors (261), and they are at increased risk of illness (262–265) and mortality (266).”
BackgroundScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 1×
“Declining cholinergic function (69–71), reductions in synaptic density (71, 72), and the loss of neurons (71, 73–75) are also consistent features of Alzheimer’s disease.”
BackgroundAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 5×
“dardization of measurement of beta-amyloid(1-42) in cere-”
BackgroundInfluentialRoth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090 · cited 2×
“Other neuropsychological tests used in dementia include, but are not limited to, the Syndrom-Kurztest (164) (assessing memory, attention, naming, and object arrangement), the SevenMinute Neurocognitive Screening Battery (165) (assessing memory, orientation, visual abilities, praxis, and language skills), the Addenbroo…”
MethodLyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049 · cited 4×
“The prevalence of apathy ranges from 20 percent to 51 percent and the 5-year prevalence is estimated as 71 percent (16, 18, 21, 23); the respective prevalences are 15–54 percent and 77 percent for depression (16, 18, 21, 22, 24–27) and 10–59 percent and 62 percent for anxiety (16, 18, 21, 23, 28).”
BackgroundInfluentialMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 1×
“(302) Nationally representative sample of the US population (N 5 856) aged 71 years or older 71–79 years of age: 5.”
BackgroundCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818
Schulz, R., O'Brien, A. T., Bookwala, J., & Fleissner, K. (1995) · The Gerontologist · doi:10.1093/geront/35.6.771 · Cited by 1,765
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“Promising biomarkers and neuroimaging could have a substantial public health impact if new drug candidates, such as beta-amyloid immunotherapy or beta-sheet breakers, were found to have disease-arresting effects (170).”
BackgroundSchneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 2×
“These developments have fueled an ongoing debate over the appropriate prescribing of antipsychotics (242, 245).”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Beta-amyloid deposits may accelerate the formation of neurofibrillary tangles in brain areas associated with Alzheimer’s disease (67, 68).”
BackgroundFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“Beta-amyloid deposits may accelerate the formation of neurofibrillary tangles in brain areas associated with Alzheimer’s disease (67, 68).”
BackgroundMullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 3×
“CSF total tau tau is released from dying neurons, so total tau concentration in the CSF is thought to reflect the intensity of the neuronal damage and degeneration (168).”
BackgroundEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
Jack, C. R., Petersen, R. C., Xu, Y. C., Waring, S. C., O'Brien, P. C., Tangalos, E. G., Smith, G. E., Ivnik, R. J., & Kokmen, E. (1997) · Neurology · doi:10.1212/wnl.49.3.786 · Cited by 1,128
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia
Mathuranath, P. S., Nestor, P. J., Berrios, G. E., Rakowicz, W., & Hodges, J. R. (2000) · Neurology · doi:10.1212/01.wnl.0000434309.85312.19 · Cited by 1,029 · cited 1×
“Other neuropsychological tests used in dementia include, but are not limited to, the Syndrom-Kurztest (164) (assessing memory, attention, naming, and object arrangement), the SevenMinute Neurocognitive Screening Battery (165) (assessing memory, orientation, visual abilities, praxis, and language skills), the Addenbroo…”
MethodPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Ory, M. G., Hoffman, R. R., Yee, J. L., Tennstedt, S., & Schulz, R. (1999) · The Gerontologist · doi:10.1093/geront/39.2.177 · Cited by 991 · cited 1×
“Informal caregivers also often experience social isolation (256), financial strain (251, 259, 267), employment complications (258, 268), and disruption of relationships (258).”
BackgroundConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
Patient and Caregiver Characteristics and Nursing Home Placement in Patients With Dementia
Yaffe, K. (2002) · JAMA · doi:10.1001/jama.287.16.2090 · Cited by 903
The incidence of dementia: A meta-analysis
Jorm, A. F., & Jolley, D. (1998) · Neurology · doi:10.1212/wnl.51.3.728 · Cited by 903
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Ott, A., Breteler, M. M. B., van Harskamp, F., Claus, J. J., van der Cammen, T. J. M., Grobbee, D. E., & Hofman, A. (1995) · BMJ · doi:10.1136/bmj.310.6985.970 · Cited by 792
Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study
Steinberg, M., Shao, H., Zandi, P., Lyketsos, C. G., Welsh‐Bohmer, K. A., Norton, M. C., Breitner, J. C. S., Steffens, D. C., & Tschanz, J. T. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1858 · Cited by 780 · cited 4×
“The prevalence of apathy ranges from 20 percent to 51 percent and the 5-year prevalence is estimated as 71 percent (16, 18, 21, 23); the respective prevalences are 15–54 percent and 77 percent for depression (16, 18, 21, 22, 24–27) and 10–59 percent and 62 percent for anxiety (16, 18, 21, 23, 28).”
BackgroundInfluentialRates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758 · cited 2×
“neurotoxicity of beta-amyloid [beta(1-40)] and the”
Review: Alzheimer's Amyloid β-Peptide-Associated Free Radical Oxidative Stress and Neurotoxicity
Varadarajan, S., Yatin, S., Aksenova, M., & Butterfield, D. A. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4274 · Cited by 735
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 1×
“The accumulation of beta-amyloid seen in Alzheimer’s disease brains may be the result of faulty beta-amyloid clearance (47), cleaving of the amyloid precursor protein by enzymes to yield free beta-amyloid peptides (48), or overproduction of betaamyloid peptides caused by mutations in the amyloid precursor protein or t…”
BackgroundAntipsychotic Drug Use and Mortality in Older Adults with Dementia
Gill, S. S., Bronskill, S. E., Normand, S.-L. T., Anderson, G. M., Sykora, K., Lam, K., Bell, C. M., Lee, P. E., Fischer, H. D., Herrmann, N., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-11-200706050-00006 · Cited by 624
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
Jack, C. R., Dickson, D. W., Parisi, J. E., Xu, Y. C., Cha, R. H., O’Brien, P. C., Edland, S. D., Smith, G. E., Boeve, B. F., Tangalos, E. G., et al. (2002) · Neurology · doi:10.1212/wnl.58.5.750 · Cited by 610 · cited 1×
“Within the medial temporal lobe, the disease consistently manifests itself through atrophy of the hippocampus and parahippocampal gyrus (189), which can be visualized by using structural magnetic resonance imaging (190).”
BackgroundCohen-Mansfield, J. (2001) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00005 · Cited by 593
Livingston, G., Johnston, K., Katona, C., Paton, J., Lyketsos, C. G., & Old Age Task Force of the World Federation of Biological Psychiatry (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.1996 · Cited by 591 · cited 1×
“Studies of patient-centered behavioral interventions such as sensory stimulation or music therapy have reported positive, but short-lived effects on agitation and other symptoms (216).”
BackgroundTarlow, B. J., Wisniewski, S. R., Belle, S. H., Rubert, M., Ory, M. G., & Gallagher-Thompson, D. (2004) · Research on Aging · doi:10.1177/0164027504264493 · Cited by 588
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
Bachman, D. L., Wolf, P. A., Linn, R., Knoefel, J. E., CobbS, J., Belanger, A., D'Agostino, R. B., & White, L. R. (1992) · Neurology · doi:10.1212/wnl.42.1.115 · Cited by 527
Incidence of dementia: does gender make a difference?
Ruitenberg, A., Ott, A., van Swieten, J. C., Hofman, A., & Breteler, M. M. B. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00231-7 · Cited by 467
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
Gomez‐Isla, T., West, H. L., Rebeck, G. W., Harr, S. D., Growdon, J. H., Locascio, J. J., Perls, T. T., Lipsitz, L. A., & Hyman, B. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390110 · Cited by 378
Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C., & Wang, P. S. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061250 · Cited by 366
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362 · cited 1×
“Symptomatic treatments such as cholinesterase inhibitors and memantine, an N-methyl-D-aspartate receptor antagonist, may stabilize or slow the progression of DAT, but these effects are lost after discontinuation (219, 220).”
BackgroundPredicting Time to Nursing Home Care and Death in Individuals With Alzheimer Disease
Stern, Y. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340040030 · Cited by 359
Education and rates of cognitive decline in incident Alzheimer's disease
Scarmeas, N. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.072306 · Cited by 353 · cited 2×
“If patients with higher educational levels also have a higher cognitive reserve, then, when DAT symptoms become apparent, the pathological burden will already be more severe and widespread, and, with the cognitive reserve depleted, the patient would appear to experience cognitive decline at a more rapid rate (45, 109).”
BackgroundTarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020568013953 · Cited by 349 · cited 1×
“Many of the proteins involved in the inflammatory response do not cross the blood-brain barrier (188); controversy exists regarding the levels of cytokine and acute-phase reaction reactants in the blood following an inflammatory response (187); findings from studies comparing the levels of plasma interleukin-6 in peop…”
ResultKanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340
Clearing amyloid through the blood-brain barrier
Zlokovic, B. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02385.x · Cited by 336
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303 · cited 1×
“Galantamine is also an allosteric nicotinic receptor modulator and enhances the effect of acetylcholine on nicotinic receptors (226).”
BackgroundStandardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301
Incidence of and risk factors for hallucinations and delusions in patients with probable AD
Paulsen, J. S., Salmon, D. P., Thal, L. J., Romero, R., Weisstein–Jenkins, C., Galasko, D., Hofstetter, C. R., Thomas, R., Grant, I., & Jeste, D. V. (2000) · Neurology · doi:10.1212/wnl.54.10.1965 · Cited by 254
Accelerated risk of hypertensive blood pressure recordings among alzheimer caregivers
Shaw, W. S., Patterson, T. L., Ziegler, M. G., Dimsdale, J. E., Semple, S. J., & Grant, I. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(98)00084-1 · Cited by 211
Medial temporal lobe atrophy on MRI in dementia with Lewy bodies
Barber, R., Gholkar, A., Scheltens, P., Ballard, C., McKeith, I. G., & O’Brien, J. T. (1999) · Neurology · doi:10.1212/wnl.52.6.1153 · Cited by 210
Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project
Ganguli, M., Dodge, H. H., Chen, P., Belle, S., & DeKosky, S. T. (2000) · Neurology · doi:10.1212/wnl.54.5.1109 · Cited by 196 · cited 1×
“(293) US population-based cohort study of 1,298 rural persons aged 65 years or older 65–69 years of age: 2.”
BackgroundSkoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
Cerebral correlates of psychotic symptoms in Alzheimer's disease
Mega, M. S. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.2.167 · Cited by 189
Hutchinson, A. D., & Mathias, J. L. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100669 · Cited by 187 · cited 1×
“Some DAT patients appear to have neuropsychological deficits more prominent in one domain than in other domains (95).”
BackgroundGeula, C. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s18 · Cited by 184
Porter, V. R., Buxton, W. G., Fairbanks, L. A., Strickland, T., O'Connor, S. M., Rosenberg-Thompson, S., & Cummings, J. L. (2003) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.15.2.180 · Cited by 182 · cited 3×
“The prevalence of apathy ranges from 20 percent to 51 percent and the 5-year prevalence is estimated as 71 percent (16, 18, 21, 23); the respective prevalences are 15–54 percent and 77 percent for depression (16, 18, 21, 22, 24–27) and 10–59 percent and 62 percent for anxiety (16, 18, 21, 23, 28).”
BackgroundAccelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152
β-Amyloid induces neuritic dystrophy in vitro: similarities with Alzheimer pathology
Pike, C. J., Cummings, B. J., & Cotman, C. W. (1992) · Neuroreport · doi:10.1097/00001756-199209000-00012 · Cited by 131
Lehtim�ki, T., Pirttil�, T., Mehta, P., Wisniewski, H., Frey, H., & Nikkari, T. (1995) · Human Genetics · doi:10.1007/bf00225071 · Cited by 125
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography
Klunk, W. E., Engler, H., Nordberg, A., Bacskai, B. J., Wang, Y., Price, J. C., Bergström, M., Hyman, B. T., Långström, B., & Mathis, C. A. (2003) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(03)00092-3 · Cited by 96 · cited 1×
“Studies using the Pittsburgh Compound B, a molecule that binds preferentially to betaamyloid fibrils (203), demonstrated that brains of DAT patients had a two- to threefold greater Pittsburgh Compound B retention on positron emission tomography scans relative to cognitively intact age-matched controls, and retention w…”
MethodThe burden of Alzheimer's disease
Burns, A. (2000) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145700001905 · Cited by 94
Mann, D. M. A., Iwatsubo, T., Pickering-Brown, S. M., Owen, F., Saido, T. C., & Perry, R. H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13294-8 · Cited by 91
Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease
Scacchi, R., Gambina, G., Ruggeri, M., Martini, M. C., Ferrari, G., Silvestri, M., Schiavon, R., & Corbo, R. M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00889-1 · Cited by 83
Effects of Residence in Alzheimer Disease Special Care Units on Functional Outcomes
Phillips, C. D. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550160060039 · Cited by 76
Chappell, N. L., & Reid, R. C. (2000) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/55.4.s234 · Cited by 47
Vickrey, B. G., Mittman, B. S., Connor, K. I., Pearson, M. L., Della Penna, R. D., Ganiats, T. G., DeMonte, R. W., Chodosh, J., Cui, X., Vassar, S., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00004 · Cited by 44 · cited 1×
“Caregiver interventions may have long-term benefits because several well-designed trials of psychoeducation programs for caregivers of persons with dementia reported a decrease in the frequency of neuropsychiatric symptoms and a delay in the time to institutionalization (217, 218).”
Background
Cited by
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications
Khoury, J. E., & Luster, A. D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.08.004 · Cited by 171
Chalermpalanupap, T., Schroeder, J. P., Rorabaugh, J. M., Liles, L. C., Lah, J. J., Levey, A. I., & Weinshenker, D. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1483-17.2017 · Cited by 136
“Thus, as the sole source of NE to critical AD-associated brain regions, such as the hippocampus and frontal cortex, damage to the LC likely contributes to disease progression and severity (Mann, 1983; Zweig et al., 1989; Jalbert et al., 2008; Weinshenker, 2008; Gannon et al., 2015).”
BackgroundDietary Patterns and Alzheimer’s Disease: An Updated Review Linking Nutrition to Neuroscience
Ellouze, I., Sheffler, J., Nagpal, R., & Arjmandi, B. (2023) · Nutrients · doi:10.3390/nu15143204 · Cited by 104
“The first clinical symptoms of AD typically appear around 20 years after the initial structural changes in the brain [5,6].”
Background
Metadata
- Authors
- Jalbert, J. J., Daiello, L. A., & Lapane, K. L.
- Venue
- Epidemiologic Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05-14
- Volume
- 30
- Issue
- 1
- Pages
- 15-34
- ISSN
- 0193-936X (ISSN-L)
- 1478-6729
- OpenAlex
- W2132773811
- Cited by
- 174
- References
- 87
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.